GlassScriptPhysician profile
Steven H Lagrant
NPI 1477540789
$14,899.17
in general payments reported to CMS, 2019-2025
46 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,574 · 2020: $1,769 · 2021: $2,590 · 2022: $2,199 · 2023: $2,101 · 2024: $2,026 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,766.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,523.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,436.56 | 2021-2025 | |
| Novo Nordisk INC | $1,357.48 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,146.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,134.15 | 2019-2025 | |
| Astellas Pharma US INC | $911.15 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.11 | 2019-2025 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $780.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $550.07 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $515.87 | 2021-2025 | |
| Amarin Pharma, INC. | $480.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $453.73 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.27 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $392.02 | 2019-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $355.78 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lagrant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.